1,703€
7,92%
Echtzeit-Aktienkurs Cardiol Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der Cardiol Therapeutics Inc. Aktie
Börsenkurse Cardiol Therapeutics Inc.
| Börse Stuttgart | - | - | - | - | 1,703€ | 7,92% |
| Lang & Schwarz | - | - | - | - | 1,683€ | -0,24% |
| Tradegate | - | - | - | - | 1,683€ | 1,39% |
| Börse Frankfurt | - | - | - | - | 1,684€ | 3,82% |
| gettex | - | - | - | - | 1,683€ | -0,88% |
| Nasdaq | - | - | - | - | 1,830$ | 3,98% |
Fundamentaldaten der Cardiol Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [CAD] | - | -28,13 Mio. | -28,13 Mio. | -0,44 | - | - | - |
| 2022 [CAD] | - | -30,93 Mio. | -30,93 Mio. | -0,50 | - | - | - |
| 2021 [CAD] | 0,08 Mio. | -31,64 Mio. | -31,64 Mio. | -0,73 | - | - | 1338,94 |
| 2020 [CAD] | - | -20,64 Mio. | -20,64 Mio. | -0,69 | - | - | - |
| 2019 [CAD] | - | -13,68 Mio. | -13,68 Mio. | -0,53 | - | - | - |
| 2018 [CAD] | - | -15,89 Mio. | -15,89 Mio. | -1,03 | - | - | - |
| 2017 [CAD] | - | -1,66 Mio. | -1,66 Mio. | -0,07 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Cardiol Therapeutics Inc. Aktie
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the "ARCHER" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.